Metabolic Acidosis Clinical Trial
Official title:
Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants - Effects of Normal Saline Versus Balanced Infusates on the Incidence of Electrolyte and Acid-base Disturbances
In this study we want to show that the choice of a balanced type fluid solution for the
perioperative fluid management of patients receiving cadaveric renal transplantation results
in less occurrence of intra- and postoperative hyperkalemia, and thus the need for
postoperative dialysis. Additionally, we aim to determine whether the use of a balanced
infusion solution leads to less occurrence of metabolic acidosis and electrolyte disorders
than the use of isotonic saline.
Furthermore we want to evaluate whether perioperative fluid management with balanced
infusion solutions results in a higher frequency of primary graft function than with
administration of isotonic saline.
We will test the hypothesis that the use of "Elomel isoton"(Fresenius Kabi Austria GmbH) a
balanced infusion solution will result in less occurrence of hyperkalemia and consequent
post-transplant dialysis, less occurrence of metabolic acidosis, decreased incidence of
electrolyte disorders and higher incidence of primary graft function when compared to
isotonic saline for perioperative fluid management in patients receiving cadaveric renal
transplantation.
Background
Kidney transplantation is the treatment of choice for patients with end-stage-renal-disease
(ESRD). Successful renal transplantation improves quality of life and reduces mortality in
eligible patients when compared to hemodialysis. In 2007, 44 kidney transplantations per
million residents were performed in Austria. The number of patients with a renal transplant
has continuously risen in the last ten years. 398 kidney transplantations were performed in
Austria in 2007, of which only 61 were of living donors. This underlines the special role of
cadaveric kidney transplantation in Austria.
Several studies have demonstrated that adequate intraoperative fluid administration is
associated with earlier onset of graft function and improved graft survival in renal
transplant recipients. However, which kind of solution should be chosen for the
perioperative fluid management of renal transplant recipients remains to be clarified. A
non-governmental US survey has shown that normal saline is the most commonly used fluid for
renal transplantation. The most common cited reason for the administration of normal saline
was the lack of potassium in the solution. Balanced salt type fluids were used in only less
than 10% of kidney transplantations.
To our knowledge only three studies compared the effects of lactated ringer's solution
versus normal saline in kidney transplantation. Taken together, the application of lactated
ringer's solution led to less occurrence of metabolic acidosis, electrolyte derangements and
in one study, the appearance of hyperkalemia was eliminated by the use of lactated ringer's
instead of normal saline. However, it was also shown that the administration of lactated
ringer's during kidney transplantation led to a significant rise in lactate levels compared
to those treated with normal salin. Despite the knowledge that lactated ringer's can at
least potentially lead to a rise in lactate levels, no studies using acetate based balanced
salt type fluids have been performed so far in cadaveric renal transplantation. We therefore
propose a prospective study in which patients undergoing cadaveric kidney transplantation
will be randomized to receive either a solely acetate buffered balanced salt type fluid or a
normal saline for infusion therapy.
Clinical considerations
Postoperative hyperkalemia is a common problem in patients receiving cadaveric renal
transplantation, especially when primary graft function does not occur. Due to the
acidifying effect of isotonic saline infusion via the generation of hyperchloremic acidosis
and/or dilutional acidosis, a rise in serum potassium is only boosted. However, today
isotonic saline is the most commonly used infusion solution for the perioperative period in
renal transplantation.
The use of a balanced infusion solution, containing a metabolizable anion, such as acetate,
could result in less metabolic acidosis and therefore a decreased need for post-transplant
dialysis. Moreover, since balanced infusion solutions have a by far lower chloride content
than isotonic saline, the adverse effects of a rise in serum chloride on renal perfusion
could be avoided. This could ultimately result in improved graft function.
Preliminary studies
O'Malley et al. compared the effects of lactated Ringer's to isotonic saline in 51 renal
transplant patients. 48 patients received living donor transplantation and 3 received
cadaveric renal transplantation. 26 patients received isotonic saline and 25 lactated
Ringer's. 19% of patients receiving isotonic saline reached postassium concentrations >
6mmol/L and required treatment versus 0% in the lactated Ringer's group. 31% of patients in
the isotonic saline group versus 0% in the lactated Ringer's group required treatment for
metabolic acidosis. No effect on primary graft function could be shown.
Hadimioglu et al. randomized patients undergoing living-related kidney transplantation to
three groups receiving either isotonic saline, lactated Ringer's or Plasmalyte (a balanced
infusion solution using acetate and gluconate). No effects on potassium levels could be
shown in this study. Patients receiving isotonic saline showed significant decreases in pH,
base excess and a significant rises in serum chloride. In the lactated Ringer's group
lactate levels increased significantly. The study showed no differences in the need for
postoperative dialysis.
Khajavi et al. randomized patients undergoing kidney transplantation to either normal saline
or lactated Ringer's. The authors noticed a higher incidence of hyperkalemia and acidosis in
the isotonic saline group while 2 patients in the lactated Ringer's group lost their kidneys
due to vascular graft thrombosis.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Completed |
NCT03317444 -
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT05582824 -
Lactate Metabolism in the Hypoperfused Critically Ill
|
||
Active, not recruiting |
NCT04010630 -
Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU
|
N/A | |
Completed |
NCT02303548 -
Bicarbonate in Patients With Out-of-hospital Cardiac Arrest
|
Phase 2 | |
Recruiting |
NCT01860001 -
Incidence of Postoperative Ketosis and Metabolic Acidosis
|
N/A | |
Completed |
NCT01452412 -
Alkali Therapy in Chronic Kidney Disease
|
Phase 2/Phase 3 | |
Terminated |
NCT03710291 -
Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
|
Phase 3 | |
Completed |
NCT02476253 -
Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill
|
Phase 3 | |
Completed |
NCT05940935 -
The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations
|
||
Withdrawn |
NCT03846258 -
High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy
|
Phase 4 | |
Completed |
NCT05970094 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
Recruiting |
NCT05784389 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
Terminated |
NCT04727528 -
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02098356 -
Comparison of High Versus Low Bicarbonate Hemodialysis
|
N/A | |
Recruiting |
NCT03897101 -
Inflammation and Metabolic Acidosis at Birth (AGAIN: AutophaGy AcIdosis Newborn)
|
||
Terminated |
NCT01894594 -
Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT01293266 -
Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation
|
N/A | |
Completed |
NCT01295190 -
Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT05147051 -
Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients
|
Phase 2 |